Published in Curr Med Chem on January 01, 2009
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics. Angew Chem Int Ed Engl (2010) 1.22
Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med (2010) 1.13
Strategies for treatment in Alexander disease. Neurotherapeutics (2010) 0.98
Regulatory role of proteasome in determination of platelet life span. J Biol Chem (2013) 0.91
Proteasome activity imaging and profiling characterizes bacterial effector syringolin A. Plant Physiol (2010) 0.90
Proteasome activator 200: the heat is on... Mol Cell Proteomics (2011) 0.88
Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet Genomics (2011) 0.86
The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes. J Biol Chem (2014) 0.81
Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem (2014) 0.81
Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis. ACS Chem Neurosci (2014) 0.78
Synthesis and proteasome inhibition of lithocholic acid derivatives. Bioorg Med Chem Lett (2011) 0.78
Synthesis of Lithocholic Acid Derivatives as Proteasome Regulators. ACS Med Chem Lett (2012) 0.77
Substrate Ubiquitination Controls the Unfolding Ability of the Proteasome. J Biol Chem (2016) 0.76
The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP. Mol Biol Cell (2016) 0.75
Agouti Related Peptide Secreted Via Human Mesenchymal Stem Cells Upregulates Proteasome Activity in an Alzheimer's Disease Model. Sci Rep (2017) 0.75
The ubiquitin system. Annu Rev Biochem (1998) 43.36
Intracellular protein degradation in mammalian and bacterial cells: Part 2. Annu Rev Biochem (1976) 12.05
The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem (1999) 8.97
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
Intracellular protein degradation in mammalian and bacterial cells. Annu Rev Biochem (1974) 6.05
Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol (2005) 4.84
Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl (2003) 4.50
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett (1998) 3.32
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 3.28
Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res (2006) 3.10
Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol (2005) 2.73
The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem (1999) 2.72
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol (2004) 2.65
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res (2001) 2.65
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem (2006) 2.59
20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev (2007) 2.47
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem (1996) 2.44
Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med (1995) 2.43
Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae. Int J Syst Evol Microbiol (2005) 2.42
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res (2003) 2.27
Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol (2004) 2.27
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
PA200, a nuclear proteasome activator involved in DNA repair. EMBO J (2002) 2.15
Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell (2008) 2.12
Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A (2000) 2.04
The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry". Mol Pharmacol (2006) 1.95
Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res (2008) 1.92
Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot (Tokyo) (1991) 1.86
A high molecular weight protease in the cytosol of rat liver. I. Purification, enzymological properties, and tissue distribution. J Biol Chem (1986) 1.86
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A (1998) 1.69
Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys (2001) 1.67
The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem J (2000) 1.62
The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. Parasitology (2005) 1.46
Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem (2000) 1.45
Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) (1992) 1.44
A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. Proc Natl Acad Sci U S A (1994) 1.39
LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol (2007) 1.35
Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot (Tokyo) (1991) 1.34
Retroviruses have differing requirements for proteasome function in the budding process. J Virol (2003) 1.34
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun (1995) 1.29
Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci U S A (1994) 1.29
Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci (2004) 1.28
Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob Agents Chemother (2001) 1.27
Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest (2000) 1.27
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res (2002) 1.25
Activation of the multicatalytic proteinase from rat skeletal muscle by fatty acids or sodium dodecyl sulphate. Biochem J (1985) 1.23
26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem (2001) 1.23
Methylation suppresses the proteasome-inhibitory function of green tea polyphenols. J Cell Physiol (2007) 1.22
Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res (1996) 1.19
Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry. J Med Chem (1996) 1.16
Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob Agents Chemother (2004) 1.13
Activation and inhibition of the proteasome by betulinic acid and its derivatives. FEBS Lett (2007) 1.12
TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J Antibiot (Tokyo) (2000) 1.12
Broad in vitro efficacy of plant-derived betulinic acid against cell lines derived from the most prevalent human cancer types. Cancer Lett (2006) 1.11
The 11S regulators of 20S proteasome activity. Curr Top Microbiol Immunol (2002) 1.11
Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS One (2007) 1.10
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Int J Cancer (2006) 1.07
The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol (1999) 1.06
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood (2004) 1.01
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res (2003) 1.01
The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts. Rejuvenation Res (2007) 1.01
A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg Med Chem Lett (2007) 0.96
Molecular basis for proline- and arginine-rich peptide inhibition of proteasome. J Mol Biol (2008) 0.92
Synthesis and anti-ulcer activity of new derivatives of glycyrrhetic, oleanolic and ursolic acids. Farmaco (1998) 0.92
Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors. Klin Padiatr (1999) 0.90
In vitro activation of the 20S proteasome. Enzyme Protein (1993) 0.89
Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg Med Chem Lett (2005) 0.89
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives. Bioorg Med Chem (2008) 0.88
Development and characterization of proteasome inhibitors. Methods Enzymol (2005) 0.87
Plasmodium falciparum: the fungal metabolite gliotoxin inhibits proteasome proteolytic activity and exerts a plasmodicidal effect on P. falciparum. Exp Parasitol (2005) 0.86
Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors. J Med Chem (2008) 0.85
Activation of 20S proteasomes from spinach leaves by fatty acids. Plant Cell Physiol (1996) 0.85
Synthetic peptide-based activators of the proteasome. Mol Biol Rep (1997) 0.84
Biosynthesis of lactacystin. J Antibiot (Tokyo) (1995) 0.84
A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. Biochem Pharmacol (2004) 0.84
Belactosin A, a novel antitumor antibiotic acting on cyclin/CDK mediated cell cycle regulation, produced by Streptomyces sp. J Antibiot (Tokyo) (2000) 0.84
Vibrational spectroscopy of betulinic acid HIV inhibitor and of its birch bark natural source. Talanta (2002) 0.84
Selective activation of the 20 S proteasome (multicatalytic proteinase complex) by histone h3. Biochemistry (2001) 0.83
Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol (1999) 0.83
Potent inhibitors of proteasome. J Med Chem (1995) 0.83
Proteasome (multicatalytic proteinase) of sea urchin sperm and its possible participation in the acrosome reaction. Mol Reprod Dev (1991) 0.83
TMC-86A, B and TMC-96, new proteasome inhibitors from Streptomyces sp. TC 1084 and Saccharothrix sp. TC 1094. II. Physico-chemical properties and structure determination. J Antibiot (Tokyo) (2000) 0.82
TMC-89A and B, new proteasome inhibitors from streptomyces sp. TC 1087. J Antibiot (Tokyo) (2000) 0.81
Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Biochem Pharmacol (2007) 0.81
Human erythrocyte multicatalytic proteinase: activation and binding to sulfated galacto- and lactosylceramides. Biochem Biophys Res Commun (1991) 0.80
The neuritogenesis inducer lactacystin arrests cell cycle at both G0/G1 and G2 phases in neuro 2a cells. J Antibiot (Tokyo) (1995) 0.79
Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) (2001) 0.79
Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. Biochem J (1993) 0.78
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol (2004) 2.65
The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology (2004) 1.70
Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem (2005) 1.66
Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med (2005) 1.48
Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. Virology (2005) 1.28
Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. Bioorg Med Chem (2005) 1.24
Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. J Med Chem (2012) 1.18
Bifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob Agents Chemother (2004) 1.13
Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem (2010) 0.95
Induction of a nonproductive conformational change in gp120 by a small molecule HIV type 1 entry inhibitor. AIDS Res Hum Retroviruses (2007) 0.92
Molecular targets of anti-HIV-1 triterpenes. Curr Drug Targets Infect Disord (2002) 0.89
Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett (2009) 0.86
Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. Virology (2004) 0.83
Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. Curr Pharm Des (2003) 0.83
Neutralization epitopes of the HIV-1 primary isolate DH012. Vaccine (2003) 0.82
Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. ChemMedChem (2014) 0.81
Discovery of novel 5-fluoro-N(2),N(4)-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9. Medchemcomm (2015) 0.76
Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome. Eur J Med Chem (2015) 0.75